A recent study found that Abilify reduced symptoms such as aggression, hyperactivity, and impulsivity in 56% of 32 children with developmental disabilities.
Unfortunately weight gain occurred in all the children during the course of the study, and three discontinued the medication because of weight gain. The mean body mass index increased from 22.5 to 24.1 kg/m2 during the follow-up period.
This is the first report I have seen about Abilify causing weight gain. Abilify, along with Geodon, was supposed to be a weight-neutral antipsychotic. I find this study especially concerning because a large part of my practice is treating the devolpmentally disabled, the population treated in this study.